2025-523503-30-00招募中2 期
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 51
- 试验地点
- 20
- 主要终点
- Change from Baseline to Week 4 in MSL for E2086 Compared With Placebo Across Four MWTs in Participants With NT1 and NT2
研究概览
简要总结
The primary purpose of this study is to evaluate the optimal doses of E2086 compared to placebo in subjects with narcolepsy for reduction of excessive daytime sleepiness (EDS) as assessed by Mean Sleep Latency (MSL) (measured from the first 4 maintenance of wakefulness tests [MWTs]).
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Male or female, age ≥18 years (or as regionally appropriate) at the time of informed consent
- •NT1 Cohort: Must fulfill Inclusion Criteria 2a and 2b a. Diagnosis of NT1 within the last 10 years of screening, as confirmed by at least one of the following: ◦ Polysomnography (PSG) and Multiple Sleep Latency Test (MSLT) results, and clinical history, consistent with the 2023 International Classification of Sleep Disorders, 3rd edition, text revision (ICSD-3-TR) criteria for NT1 ◦ Cerebrospinal fluid orexin-A/hypocretin-1 concentration less than or equal to (<=) 110 picograms per milliliter (pg/mL) b. At least 4 or more episodes of cataplexy/week as averaged over 2 weeks minimum and confirmed by the cataplexy portion of the Diary If PSG or MSLT results are not available within the last 10 years of screening to fulfill Criterion 2a then screening assessment results for PSG or MSLT can be used instead
- •NT2 Cohort: Diagnosis of NT2 within the last 10 years of screening, as confirmed by PSG and MSLT results, and clinical history, consistent with the 2023 ICSD-3-TR criteria for NT2 If PSG or MSLT results are not available within the last 10 years of screening to fulfill Criterion 3 then screening assessment results for PSG or MSLT can be used instead
- •ESS score ≥10
- •Reports regular bedtime, defined as the time that the subject attempts to sleep, between 22:00 and 01:00 (based on data from the screening Diary)
- •Reports regular waketime, defined at the time the subject gets out of bed for the day, between 05:00 and 10: 00 (based on data from the screening Diary)
- •Reports being in bed between 7 and 9 hours per night (based on data from the sleep portion of the Diary)
- •Compliance rate ≥80% for completion of the Diary during screening
- •Body mass index (BMI) >=18 to less than (<) 35 kilograms per square meter (kg/mˆ2) at Screening
排除标准
- •Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin [hCG]) test with a minimum sensitivity of 25 IU/L or equivalent units of ß-hCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug
- •Known to be human immunodeficiency virus (HIV) positive
- •Acute Epstein Barr virus (EBV) infection with a positive EBV Viral Capsid Antigen Antibody (VCA) IgM at Baseline
- •Females of childbearing potential who: • Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following: a. total abstinence (if it is their preferred and usual lifestyle) b. an intrauterine device or intrauterine hormone-releasing system (IUS) c. a contraceptive implant d. Combined estrogen and progestogen-containing hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception associated with inhibition of ovulation, such as desogestrel (oral, injectable). Subjects using hormonal contraceptives must be on a stable dose of the same contraceptive product for at least 28 days before dosing, throughout the study and for at least 28 days following study drug discontinuation e. have a vasectomized partner with confirmed azoospermia • Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation. Subjects on an oral contraceptive must use an additional contraception method throughout the study and for 28 days after study drug discontinuation. For sites outside of Europe, it is permissible that if a highly effective method of contraception is not appropriate or acceptable to the subject, then the subject must agree to use a medically acceptable method of contraception, ie, double-barrier methods of contraception such as latex or synthetic condom plus diaphragm or cervical/vault cap with spermicide. NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
- •Known to be hepatitis B virus (HBV)-positive with a detectable HBV (for example, hepatitis B surface antigen [HBsAg] reactive) within 6 months before the 1st dose of study drug, or hepatitis C virus (HCV) positive with a detectable (for example, HCV ribonucleic acid (RNA) [qualitative]) viral load. Note: Subjects who are HCV positive due to prior resolved disease can be enrolled, only if a confirmatory negative HCV RNA test is obtained and the subject has completed active treatment
- •History of formally diagnosed moderate to severe obstructive sleep apnea (OSA)
- •Current use of continuous positive airway pressure (CPAP), hypoglossal nerve stimulator, oral device, or other therapy for the treatment of OSA
- •Symptomatic restless legs syndrome
- •Apnea-hypopnea index >=15 on Screening PSG
- •Use of anticataplectic medications (including but not limited to antidepressants) within 5× the half-life before initiating collection of Diary data during the Screening Period
- •Use of psychostimulant medications, prescription and over-the-counter (OTC), within 5× the half-life before initiating collection of Diary data during the Screening period until after the Follow-Up Visit. Examples of prohibited medications include OTC stimulants (for example, pseudoephedrine), methylphenidate, amphetamines, modafinil, armodafinil, sodium oxybate, pitolisant, solriamfetol, and pemoline
- •Any lifetime history of, or current, suicidal behavior as indicated by the C–SSRS
- •Use of sleep promoting or sedating medications, prescription and OTC, within 5x the half-life before initiating collection of Diary data during the Screening period until after the Follow-Up Visit. Examples of prohibited medication include OTC sleep aids, trazodone, hypnotics, benzodiazepines, barbiturates, cannabinoids, melatonin, melatonin receptor agonists, dual orexin receptor antagonists, and opioids
- •Inability to discontinue use of strong (such as antifungal itraconazole and antibiotic clarithromycin) and moderate (such as antifungal fluconazole) Cytochrome P450 3A (CYP) 3A inhibitors within 5x the half-life before dosing until after the Follow-Up Visit
- •Clinically significant illness that requires medical treatment within 8 weeks of dosing or a clinically significant infection that requires medical treatment within 4 weeks of dosing
- •Inability to discontinue use of CYP3A inducers (such as antibiotic rifampicin and anti-convulsant phenytoin) within 5x the half-life before dosing until after the Follow-Up Visit
- •History of drug or alcohol dependency or abuse within 2 years before Screening, or those who have a positive urine drug test or breath (or urine) alcohol test at Screening or Baseline
- •Does not agree to abstain from use of recreational drugs during the study
- •Currently enrolled in another clinical study or used any investigational drug or device within 28 days or 5x the half-life, whichever is longer, preceding informed consent
- •Receipt of blood products within 4 weeks of dosing, donation of blood within 8 weeks of dosing, or donation of plasma within 1 week of dosing
- •Past participation in a study of an orexin agonist if discontinuation of orexin agonist use was related to an adverse drug reaction or inefficacy
- •Evidence of disease that may influence the outcome of the study within 4 weeks before dosing (for example, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system)
- •Current unstable psychiatric disorder, current active major depressive episode or an active major depressive episode in the past 6 months. An unstable psychiatric disorder is defined as acute crisis, hospitalization, or significant change in treatment in the last 6 months.
- •Any history of surgery that may affect PK profiles of E2086 (for example, hepatectomy, nephrectomy, digestive organ resection) or who have a congenital abnormality in metabolism at Screening
- •Any clinically abnormal symptom or organ impairment found by medical history at Screening, including moderate or severe renal impairment (estimated glomerular filtration rate [eGFR] <60 milliliters per minute (mL/min), and physical examinations, vital signs, ECG findings, or laboratory test results that require medical treatment at Screening or Baseline
- •A prolonged QTc interval calculated using Fridericia’s formula (QTcF) greater than 450 milliseconds (ms) according to central reading at Screening or Baseline. If the QTcF machine read is greater than 450 ms on the first single 12-lead ECG, 2 additional 12-lead ECGs will be performed 1 minute apart and the mean of the 3 QTcF values will be calculated
- •Persistent systolic BP greater than (>) 130 or <100 millimeters of mercury (mmHg) or diastolic BP >85 or <50 mmHg at Screening (based on BP measured on at least 3 occasions over 2 weeks), or at Baseline. If outside of these limits at Screening or Baseline, BP should be repeated twice with at least 5 minutes between measurements
- •Persistent HR less than 50 beats/min or more than 100 beats/min at Screening (based on HR measured on at least 3 occasions over 2 weeks), or at Baseline. If outside of these limits at Screening or Baseline, HR should be repeated twice with at least 5 minutes between measurements
- •Any suicidal ideation with intent with or without a plan at Screening or within 6 months of Screening (that is, answering “Yes” to questions 4 or 5 on the Suicidal Ideation section of the C–SSRS). For sites in Europe, any history of or current suicidal ideation according to the C-SSRS.
- •Psychotic disorder(s) or unstable recurrent affective disorder(s) evident by use of antipsychotics within 2 years before Screening. For sites in Europe, any history of or current psychotic disorder.
- •Hypersensitivity to the study drug or any of the excipients
- •Intake of herbal preparations containing St. John’s Wort within 1 week before dosing
- •Any history of or concomitant medical condition that in the opinion of the investigator(s) would compromise the subject’s ability to safely complete the study
- •Planned surgery that requires general, spinal, or epidural anesthesia that would take place during the study. Planned surgery which requires only local anesthesia and that can be undertaken as a day case without inpatient stay postoperatively need not result in exclusion if in the opinion of the investigator this operation does not interfere with study procedures and subject safety
研究组 & 干预措施
E2086, E2086, E2086, E2086, E2086
Test
干预措施: E2086 (Drug)
Tablets that match the E2086 tablets in both shape and appearance.
Placebo
干预措施: Tablets that match the E2086 tablets in both shape and appearance. (Drug)
结局指标
主要结局
Change from Baseline to Week 4 in MSL for E2086 Compared With Placebo Across Four MWTs in Participants With NT1 and NT2
Change from Baseline to Week 4 in MSL for E2086 Compared With Placebo Across Four MWTs in Participants With NT1 and NT2
Change from Baseline to Week 4 in MSL for E2086 Compared With Placebo Across Four MWTs in Subjects With NT1 and NT2
Change from Baseline to Week 4 in MSL for E2086 Compared With Placebo Across Four MWTs in Subjects With NT1 and NT2
次要结局
- Weekly Cataplexy Rate (WCR) of E2086 Compared With Placebo at Week 4 in Participants With NT1
- Change From Baseline in the Epworth Sleepiness Scale (ESS) Total Score to Week 4 for E2086 Compared With Placebo in Participants With NT1 and NT2
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Participants With NT1 and NT2
- Number of Participants With Markedly Abnormal Laboratory Values in Participants With NT1 and NT2
- Number of Participants With Clinically Significant Changes in Vital Sign Values in Participants With NT1 and NT2
- Number of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Parameters in Participants With NT1 and NT2
- Number of Participants With Suicidality as Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS) in Participants With NT1 and NT2
- Mean Change From Baseline in 24-hours Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) up to Week 4 of each dose level in Participants With NT1 and NT2
- Mean Change From Baseline in Day-time and Night-time BP Measured by ABPM in Participants With NT1 and NT2
- Cmax: Maximum Observed Plasma Concentration of E2086 and its Metabolite M1
- Tmax: Time to Reach Cmax of E2086 and its Metabolite M1
- AUC(0-24h): Area Under the Plasma Concentration–time Curve From Zero Time to 24 Hours of E2086 and its Metabolite M1
- t½: Terminal Phase Half-life of E2086 and its Metabolite M1
- MRp: Metabolite Ratio of AUC(0-t)
- Number of Subjects With Clinically Significant Changes in Vital Sign Values in Subjects With NT1 and NT2
- Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Subjects With NT1 and NT2
- Number of Subjects With Markedly Abnormal Laboratory Values in Subjects With NT1 and NT2
- Weekly Cataplexy Rate (WCR) of E2086 Compared With Placebo at Week 4 in Subjects With NT1
- Change From Baseline in the Epworth Sleepiness Scale (ESS) Total Score to Week 4 for E2086 Compared With Placebo in Subjects With NT1 and NT2
- Number of Subjects With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Parameters in Subjects With NT1 and NT2
- Number of Subjects With Suicidality as Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS) in Subjects With NT1 and NT2
- Mean Change From Baseline in 24-hours Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) up to Week 4 of each dose level in Subjects With NT1 and NT2
- Mean Change From Baseline in Day-time and Night-time BP Measured by ABPM in Subjects With NT1 and NT2
研究者
Medical Information
Scientific
Eisai Limited
研究点 (20)
Loading locations...
相似试验
招募中
2 期
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With NarcolepsyNCT07493265Eisai Inc.64
招募中
2 期
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of TreatmentChronic Obstructive Pulmonary Disease (COPD)NCT07684820Expedition Therapeutics, Inc600
招募中
2 期
A Study of E6742 in Participants With Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT07515014Eisai Co., Ltd.256
尚未招募
2 期
A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in ObesityOverweight or ObesityNCT07690826Fujian Shengdi Pharmaceutical Co., Ltd.252
尚未招募
2 期
Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)Moderately to Severely Active Ulcerative Colitis (UC)NCT07535489Nanjing Immunophage Biotech Co., Ltd144